ADIAL PHARMACEUTICALS, INC. current report, 19 May 2023

Full document

Business Context and Reporting Period

Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: May 19, 2023
Reporting Period: The filing addresses compliance status as of March 31, 2023, and current listing requirements on The Nasdaq Capital Market.

Key Financial Metrics

The filing provides limited financial data, focusing on equity levels required for listing compliance:

  • Stockholders' Equity: $1,439,848 as of March 31, 2023 (reported in the Form 10-Q filed May 12, 2023).
  • Minimum Equity Requirement: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
  • Market Value of Listed Securities: The filing states the Company does not meet the $35 million alternative standard.
  • Net Income: The filing states the Company does not meet the $500,000 net income alternative standard for the most recent fiscal year or two of the last three fiscal years.
  • Revenue, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide clear values for these specific metrics.

Material Changes and Listing Deficiencies

The Company received a notification from Nasdaq regarding two separate listing deficiencies:

  1. Stockholders' Equity Deficiency: The Company's equity of $1,439,848 is below the $2,500,000 minimum requirement. The Company has 45 calendar days (until July 3, 2023) to submit a Compliance Plan. If accepted, an extension of up to 180 days may be granted to regain compliance.
  2. Minimum Bid Price Deficiency: The Company previously failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The compliance period was extended to August 28, 2023. Compliance requires the stock to close at or above $1.00 for 10 consecutive business days prior to this date.

Outlook, Risks, and Management Commentary

Management Actions:

  • The Company intends to submit a Compliance Plan for the equity deficiency by July 3, 2023.
  • The Company is considering available options to regain compliance, including effecting a reverse stock split.
  • The Company will actively monitor its stockholders' equity and bid price.
Risks and Contingencies:
  • There is no assurance that the Compliance Plan will be accepted by Nasdaq.
  • If the Company fails to regain compliance with the Minimum Bid Price Requirement by August 28, 2023, Nasdaq will provide written notification of delisting.
  • While the Company has the right to appeal a delisting determination to a Hearing Panel, there is no assurance such an appeal would be successful.
  • Failure to maintain listing could result in suspension or delisting of the Company's common stock and warrants.

Investor Verification Checklist

  • Verify the acceptance status of the Compliance Plan for the Stockholders' Equity deficiency by July 3, 2023.
  • Monitor the daily closing bid price of ADIL common stock to ensure it meets the $1.00 threshold for 10 consecutive days before August 28, 2023.
  • Review the Form 10-Q filed on May 12, 2023, for detailed financial statements regarding revenue, cash flow, and debt not included in this 8-K.
  • Watch for announcements regarding a potential reverse stock split or other capital raising activities intended to restore equity levels.
  • Confirm whether the Company has filed an appeal with the Nasdaq Hearing Panel if delisting notifications are issued.